Antares Pharma (ATRS) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Antares Pharma Reports First Quarter 2016 Operating and Financial Results
May 9, 2016 7:01 AM EDTEWING, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the first quarter ended March 31, 2016. The Company reported revenue of $12.3 million compared to $8.3 million for the comparable period in 2015, and net loss per share of $0.05 for both periods.Â
The Company reported another solid quarter of top line growth, with the primary driver of that growth coming once again from an increase in product revenue, said Robert F. Apple, President and Chief Executive Officer of the Company. Antares also reported significant progress... More
